Page 1 of 6
This document provides a short summary of this study for a general audience. You can
find more information in the scientific summary of the study. A link to the summary is
provided at the end of this document.
Study names
Short Title: A study to learn about the effect of daprodustat on blood pressure in
patients with anaemia due to chronic kidney disease.
Full Scientific Title: A randomised, open label study to evaluate the effect of
daprodustat on blood pressure in subjects with anaemia associated with chronic kidney
disease on haemodialysis switched from a stable dose of an erythropoiesis-stimulating
agent.
Study Number: 205665
Who sponsored this study?
GlaxoSmithKline (GSK)
GSK Clinical Support Help Desk
Website: clinicalsupporthd.gsk.com/contact.html
Email: GSKClinicalSupportHD@gsk.com
General information about the clinical study
When and where was this study done?
The study started in July 2017 and ended in July 2020. All study sites were in the United
States.
What was the main reason for this study?
Chronic kidney disease (CKD) is a long-term disease of the kidneys. Some people with
CKD cannot make enough of a protein that carries oxygen in the blood (haemoglobin).
This condition is called renal anaemia.
Use of the data and information contained in this Document is unrestricted, provided that it may not
be used in applications by others for regulatory approval of a product. While not required, when using
these data, we ask that proper credit or attribution of GSK as the source of the data be given. GSK
disclaims liability for all uses of the data by users of this Document, to the fullest extent permitted by
applicable law. No trademark, patent, or regulatory/data exclusivity rights held by GSK are waived,
licensed or otherwise affected.